Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Brain Cancer

Brain Cancer

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Brain Cancer

232 trials tracked for Brain Cancer: 18 in phase 3 or 4 and 6 with published results. The most-cited published study has 1175 citations.

232Trials tracked
18Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 6 Phase 3 12 Phase 2 166 Phase 1 21 Other / NA 27
  1. Phase 3 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed · 1,175 cited
  2. Phase 3 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 539 cited
  3. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 525 cited
  4. Phase 3 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed · 25 cited
  5. Phase 3 Hypovitaminosis D in Neurocritical Patients Completed · 22 cited
  6. Phase 4 Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Completed
Show 44 more trials
  1. Phase 4 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed
  2. Phase 4 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed
  3. Phase 4 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed
  4. Phase 4 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients Completed
  5. Phase 4 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed
  6. Phase 3 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Completed
  7. Phase 3 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed
  8. Phase 3 Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas Completed
  9. Phase 3 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed
  10. Phase 3 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed
  11. Phase 3 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed
  12. Phase 3 Comparing Two Forms of Head Immobilization for Stereotactic Radiotherapy Completed
  13. Phase 2 Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Completed
  14. Phase 2 Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed
  15. Phase 2 A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas Completed
  16. Phase 2 Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide Completed
  17. Phase 2 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Completed
  18. Phase 2 Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. Completed
  19. Phase 2 Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas Completed
  20. Phase 2 Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma Completed
  21. Phase 2 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Completed
  22. Phase 2 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Completed
  23. Phase 2 Low Dose Naltrexone for Glioma Patients Completed
  24. Phase 2 Pazopanib in Treating Patients With Recurrent Glioblastoma Completed
  25. Phase 2 LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma Completed
  26. Phase 2 Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Completed
  27. Phase 2 Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma Completed
  28. Phase 2 Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Completed
  29. Phase 2 Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Completed
  30. Phase 2 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma Completed
  31. Phase 2 Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed
  32. Phase 2 Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma Completed
  33. Phase 2 Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed
  34. Phase 2 Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma Completed
  35. Phase 2 Study of MEK162 for Children With Low-Grade Gliomas Completed
  36. Phase 2 Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform Completed
  37. Phase 2 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Completed
  38. Phase 2 Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma Completed
  39. Phase 2 Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas Completed
  40. Phase 2 PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children Completed
  41. Phase 2 Nivolumab for Recurrent or Progressive IDH Mutant Gliomas Completed
  42. Phase 2 Bevacizumab Beyond Progression (BBP) Completed
  43. Phase 2 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Completed
  44. Phase 2 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed

Showing the 50 most-cited and recently-updated of 232 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Brain Cancer: what the trials found

Several pharmacological interventions have been evaluated for brain cancer management. Nivolumab demonstrated significant results in one study, where a comparison of overall survival (OS) showed a statistically significant difference (p=0.0037) with OS rates at 24 months reaching 10.6% and 21.2% respectively 9. In another trial involving Nivolumab, overall survival was reported as 28.91, 32.07, 31.34, and 32.99 (p=0.3402), with 12-month OS rates of 82.7% and 87.7% and 24-month OS rates of 55.9% and 63.3% 8.

Temozolomide was evaluated in multiple trials, including a large Phase 3 study 7 and a study assessing concurrent temozolomide, which showed median overall survival times of 16.6 and 14.9 (p=0.63) and median progression-free survival (PFS) times of 5.5 and 6.7 (p=0.06) 15. Other interventions include Bevacizumab 13, Carboplatin, where complete response rates and event-free survival (EFS) were measured 14, and Elucirem 12.

Supportive and diagnostic measures include Dotarem®, which showed high rates of good or excellent lesion visualization and characterization (ranging from 90.6% to 100.0%) 5. Levetiracetam was evaluated regarding neurotoxicity, showing no significant change in scores (p=0.7824) 1. Perampanel was associated with zero reported adverse events 4. Other interventions include stereotactic body radiotherapy 3, filgrastim 16, and an educational intervention 18.

A study on BCNU 80mg/m2 reported no significant difference in overall survival (p=0.36) or time to tumor progression (p=0.46), but showed a significant difference in the number of patients experiencing Grade 3 or higher toxicity (p=<0.001) 10. Cholecalciferol did not show a statistically significant difference in hospital length of stay (p=0.2) or ICU length of stay (p=0.3) 11.

Recent results — preliminary, needs further review

  • MEK162 was evaluated in a Phase 2 trial 20.

For the clinician treating this condition

  • Nivolumab showed statistically significant differences in overall survival in one study 9, while another study showed no significant difference in survival metrics 8.
  • Concurrent temozolomide showed no statistically significant difference in median overall survival or progression-free survival 15.
  • Dotarem® demonstrated high consistency in lesion visualization and characterization 5.
  • BCNU 80mg/m2 was associated with significantly different rates of Grade 3 or higher toxicity 10.

AI synthesis of 16 cited trials, updated Sep 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.